New hybrid Aspirin is the next weapon of choice against mesothelioma, according to a study at The City College of New York.
The research, published in the ACS Medicinal Chemistry Letters, claims that this new compound can actively target cancer cells.
Up to now the only treatments to cancer sufferers are surgery, radiation and chemotherapy. Mesothelioma itself is particularly resistant to these methods, and as of yet there is still no known cure.
One of the main problems with the existing treatments for mesothelioma is that they are highly toxic. Its effects on healthy cells can produce exceptionally strong side effects, to the point where there becomes no benefit for the sufferer.
One of the main advantages to this new aspirin compound is that it targets specifically the cancerous cells.
Research found that compound helped shrink existing tumours and slow cancerous growth. Although the research is still in its infancy, and may take many years to be a finished product, there is hope for mesothelioma sufferers that there may finally be a breakthrough